September 21, 2015 — Zoll Medical Corp. announced that it has acquired Tel Aviv, Israel-based Kyma Medical Technologies Ltd., which develops technologies to measure early signs of congestive heart failure.
Currently, Kyma is developing a remote patient monitoring system for fluid management in a variety of patients including those suffering from heart failure. This µ-Cor System uses radio frequency-based technology to monitor the level of fluid in the lungs. It also collects data on heart rate, respiration rate, activity and posture, all of which are analyzed using proprietary algorithms to determine patient-specific vital signs trends. Once a potential deterioration in the patient’s condition is identified, a notification is sent to the patient’s medical team.
“The acquisition of Kyma Medical will allow Zoll to broaden its product offerings with additional technologies designed to improve outcomes for heart failure patients with fluid management problems, with the goal of reducing hospitalizations," said Jason T. Whiting, president of Zoll LifeVest. “With the acquisition, Kyma’s technology will be able to better reach global markets through Zoll’s existing network. Additionally, we expect to leverage Kyma’s strong R&D capabilities as well as the broader research talent available in Israel.”
In January 2015, Kyma announced that it had received CE Mark approval for the µ-Cor System for monitoring thoracic fluid content, electrocardiograms (ECG), heart rate, respiration rate, activity and posture.
Zoll plans to maintain Kyma’s facilities and workforce in Israel and California as a part of Zoll’s LifeVest division.
For more information: www.zoll.com
April 16, 2024 
